Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Older people are at a greater risk of medicine-induced toxicity resulting from either increased drug sensitivity or age-related pharmacokinetic changes. The scenario is further complicated with the two most prevalent age-related neurodegenerative diseases, Alzheimer's disease (AD) and Parkinson's disease (PD). With aging, AD and PD, there is growing evidence of altered structure and function of the blood-brain barrier (BBB), including modifications to tight junctions and efflux transporters, such as P-glycoprotein. The subsequent impact on CNS drug exposure and risk of neurotoxicity from systemically-acting medicines is less well characterized. The purpose of this review, therefore, is to provide an overview of the multiple changes that occur to the BBB as a result of aging, AD and PD, and the impact that such changes have on CNS exposure of drugs, based on studies conducted in aged rodents or rodent models of disease, and in elderly people with and without AD or PD.

Original languageEnglish
Pages (from-to)62-74
Number of pages13
JournalAdvanced Drug Delivery Reviews
Volume135
DOIs
Publication statusPublished - Oct 2018

Keywords

  • Aging
  • Alzheimer's disease
  • Blood-brain barrier
  • Neurodegenerative disease
  • P-glycoprotein
  • Parkinson's disease

Cite this

@article{ee0026a7383a4776af5a96c8090088a5,
title = "Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics",
abstract = "Older people are at a greater risk of medicine-induced toxicity resulting from either increased drug sensitivity or age-related pharmacokinetic changes. The scenario is further complicated with the two most prevalent age-related neurodegenerative diseases, Alzheimer's disease (AD) and Parkinson's disease (PD). With aging, AD and PD, there is growing evidence of altered structure and function of the blood-brain barrier (BBB), including modifications to tight junctions and efflux transporters, such as P-glycoprotein. The subsequent impact on CNS drug exposure and risk of neurotoxicity from systemically-acting medicines is less well characterized. The purpose of this review, therefore, is to provide an overview of the multiple changes that occur to the BBB as a result of aging, AD and PD, and the impact that such changes have on CNS exposure of drugs, based on studies conducted in aged rodents or rodent models of disease, and in elderly people with and without AD or PD.",
keywords = "Aging, Alzheimer's disease, Blood-brain barrier, Neurodegenerative disease, P-glycoprotein, Parkinson's disease",
author = "Yijun Pan and Nicolazzo, {Joseph A.}",
year = "2018",
month = "10",
doi = "10.1016/j.addr.2018.04.009",
language = "English",
volume = "135",
pages = "62--74",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. / Pan, Yijun; Nicolazzo, Joseph A.

In: Advanced Drug Delivery Reviews, Vol. 135, 10.2018, p. 62-74.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics

AU - Pan, Yijun

AU - Nicolazzo, Joseph A.

PY - 2018/10

Y1 - 2018/10

N2 - Older people are at a greater risk of medicine-induced toxicity resulting from either increased drug sensitivity or age-related pharmacokinetic changes. The scenario is further complicated with the two most prevalent age-related neurodegenerative diseases, Alzheimer's disease (AD) and Parkinson's disease (PD). With aging, AD and PD, there is growing evidence of altered structure and function of the blood-brain barrier (BBB), including modifications to tight junctions and efflux transporters, such as P-glycoprotein. The subsequent impact on CNS drug exposure and risk of neurotoxicity from systemically-acting medicines is less well characterized. The purpose of this review, therefore, is to provide an overview of the multiple changes that occur to the BBB as a result of aging, AD and PD, and the impact that such changes have on CNS exposure of drugs, based on studies conducted in aged rodents or rodent models of disease, and in elderly people with and without AD or PD.

AB - Older people are at a greater risk of medicine-induced toxicity resulting from either increased drug sensitivity or age-related pharmacokinetic changes. The scenario is further complicated with the two most prevalent age-related neurodegenerative diseases, Alzheimer's disease (AD) and Parkinson's disease (PD). With aging, AD and PD, there is growing evidence of altered structure and function of the blood-brain barrier (BBB), including modifications to tight junctions and efflux transporters, such as P-glycoprotein. The subsequent impact on CNS drug exposure and risk of neurotoxicity from systemically-acting medicines is less well characterized. The purpose of this review, therefore, is to provide an overview of the multiple changes that occur to the BBB as a result of aging, AD and PD, and the impact that such changes have on CNS exposure of drugs, based on studies conducted in aged rodents or rodent models of disease, and in elderly people with and without AD or PD.

KW - Aging

KW - Alzheimer's disease

KW - Blood-brain barrier

KW - Neurodegenerative disease

KW - P-glycoprotein

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85046153921&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.04.009

DO - 10.1016/j.addr.2018.04.009

M3 - Article

VL - 135

SP - 62

EP - 74

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -